Patients who had concurrent thrombotic thrombocytopenic purpura (TTP) and COVID-19 had elevated risk of mortality and other complications. Patients who had concurrent thrombotic thrombocytopenic ...
A new report offers novel insights into a very small patient population. Neuropsychiatric symptoms are extremely common in patients with hereditary thrombotic thrombocytopenic purpura (hTTP), making ...
The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).
A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of ...
Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...
Results showed 80% of pediatric patients achieved clinical remission. The Food and Drug Administration (FDA) has expanded the approval of Cablivi ® (caplacizumab-yhdp) to include treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results